Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept loading-dose spacing in macular edema due to central retinal vein occlusion
PACTR202201655513401Not yet recruiting
- Sponsor
- Universal Health Insurance Authority
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of aflibercept in central retinal vein occlusion (CRVO) and macular edema (2 arms), sponsored by Universal Health Insurance Authority. Primary endpoint: Best corrected visual acuity change. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)macular edema
Beyond the preview
Go deeper on PACTR202201655513401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201655513401.